Cannabis Report
Home > Boards > Canadian > Cannabis >

CannTrust Holdings (CNTTF)

Add CNTTF Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 7/13/2018 3:06:37 PM - Followers: 12 - Board type: Free - Posts Today: 0



As a federally regulated licensed producer, we bring more than 40 years of pharmacy and healthcare experience to the Medical Cannabis industry and apply this expertise to produce standardized Medical Cannabis for patients in need as we sell 100% pesticide free product.

At CannTrust™ we are committed to research and innovation, as well as contributing to the growing body of evidence-based research regarding the use and efficacy of cannabis. Our product development teams along with our exclusive Pharma partner Apotex are diligently innovating and developing products that will make it easier for patients to use Medical Cannabis today and in the future. We support ongoing patient education about Medical Cannabis, and have launched a compassionate use program to support patients with financial needs.
Our 50,000-square foot state-of-the-art hydroponic facility provides control and results, combined with a patient-centric focus, ensures we are producing quality products and delivering superior service to our customers. To satisfy the demand for our products, we are expanding our production capacity with a 430,000-square foot greenhouse in the heart of the Niagara region. The facility has been designed and engineered to ensure our customers have a continuous supply of quality standardized products. This facility will be the first of its kind in Canada, one of the largest in North America, and the first phase will come on-stream in fall 2017.

Our onsite laboratory with advanced technology and equipment for testing and research on the medical use of cannabis provides CannTrust the ability to develop and rigorously test our products at any point. CannTrust has been granted a Section 9 License by Health Canada under the Narcotic Control Regulations. This allows us to expand our product development and research to include pharmaceuticals in an effort to better serve all Patients and Customers.

Taking Top Pick Target Up - ECHLON

Event: We reiterate our Speculative Buy rating as well as our Top Pick classification, and are raising our 12-month target price from $6.25/shr to $15.00/shr. When we originally launched coverage, we noted that our estimates and target price reflected baseline forecasts that had significant upside potential. We have increased our F2019 revenue/EBITDA estimates to reflect the benefit of the planned Phase 2 expansion, which we view as fully funded following the Company’s recent equity financing (co-led by Echelon Wealth Partners). Since it began publicly trading on August 21st, TRST has been one of the top performing cannabis stocks in our tracking group, with a return of 173% against the group average of 78%. Potential catalysts include improved financial results, additional product development news and the granting of a sales license for the Niagara facility.

Investment Thesis: CannTrust Holdings is a licensed producer (LP) of medical cannabis, operating a hydroponic indoor production facility in Vaughan, Ontario, and a greenhouse facility in Fenwick, Ontario. For additional detail, please refer to our recent initiating coverage report.

???$20M Equity Financing Closed; Doubling of Niagara Capacity Fully Funded– CannTrust recently completed a $20M bought deal private placement (including full exercise of the overallotment) at $5.00/shr. This was originally announced as a $15.0M offering, but was increased given strong demand. The Company has also arranged a $15.0M mortgage on its Niagara Greenhouse facility, and we expect the lender’s credit committee to approve the mortgage shortly. We therefore believe the Phase 2 expansion is fully funded, allowing TRST to double annualized production capacity at the Niagara facility to 40,000kg by mid-2018.

???TRST Reported Strong Q317 Results, and Initial Shipments to Australia – TRST reported revenue/adjusted EBITDA of $6.1M/$1.2M, beating our original forecast of $4.8M/ ($0.8M). The revenue outperformance was driven by sales volumes that beat our estimate by 26%, with both dried cannabis and cannabis oil sales volumes better than expected. As of late last week, TRST had 35,000 active patients. Moreover, the Company recently received Health Canada approval to export medical cannabis; shipments to Australia have begun, and management expects to soon begin shipping to Germany, Denmark and Brazil.

???Capacity Increase Drives Near Doubling of F2019 EBITDA Forecast to $111M – The Phase 2 expansion should double annualized production capacity at the Niagara facility from 20,000kg to 40,000kg, with completion expected in mid-2018 (our model assumes first harvest in late 2018). This is the primary driver behind the increase in our F2019 EBITDA estimate from $57M to $111M. Absent any change in the valuation multiple (10x EV/2019E EBITDA), this would justify a target price of $11.50+. However, as the group average multiple has doubled since we initiated coverage in late August, we are increasing our valuation multiple to 13x EV/2019E EBITDA, and are raising our 12-month target to $15.00/shr from $6.25/shr.

???Our Estimates Leave Significant Upside for Better Utilization and Stronger Yields – Should F2019 production reach full utilization (vs. our 70% forecast), our EBITDA estimate and 12-month target price would improve to $154M and $21/shr, respectively. Should crop yields outperform on top of that, our EBITDA and 12-month target prices could improve to $225M and $30/shr, respectively.

Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#31   CannTrust's 3 Rec Supply Agreements To exceed 17,000kg jcamp212 07/13/18 03:06:37 PM
#30   CannTrust Danish Partner STENOCARE Receives License jcamp212 07/06/18 03:09:56 PM
#29   Quiet here GIDDY UP taubytaub 07/04/18 04:20:33 PM
#28   Good video, COO Brad Rogers talks about upcoming Powe 06/21/18 07:23:51 PM
#27   Nice close today! Anybody out there? Powe 06/20/18 04:31:06 PM
#26   Why CannTrust Holdings Revenue And Earnings Should Continue JohnCM 06/04/18 11:53:45 AM
#25   Just bought into Canntrust 2 weeks ago, surprised theresistance19 05/04/18 09:48:54 PM
#24   Up anther 10% today on Canadian side..... running OGINVU 05/04/18 11:35:42 AM
#23   Nice follow up to yesterdays run........ OGINVU 05/04/18 11:16:40 AM
#22   I really pulled in my MJ horns. JohnCM 05/01/18 04:22:27 PM
#21   In answer "what do you think about this Company?" choinvestor 05/01/18 02:06:36 PM
#20   What do you think about this company? caryPT 05/01/18 11:14:01 AM
#19   I understand for TRST that the veterinary cannabis choinvestor 04/22/18 04:57:17 PM
#18   CannTrust® Enters Veterinary Cannabis Market Through Partnership with OGINVU 04/18/18 11:20:11 AM
#17   Hard Shell Capsules OGINVU 04/18/18 11:19:13 AM
#16   CannTrust Holdings Expands Internationally into Denmark jcamp212 03/13/18 12:07:35 PM
#15 GOLD DIGGAA 03/12/18 06:20:13 AM
#14   CannTrust to Trade on the Toronto Stock Exchange jcamp212 03/02/18 03:34:17 PM
#13[/ JohnCM 02/23/18 01:16:49 PM
#12   John, you still holding this stock? What's not Thee Donald 02/23/18 03:06:42 AM
#11   CannTrust™ receives conditional approval to list on the PENNYBUSTER 02/22/18 02:49:05 PM
#10   $CNTTF Nice News Hit! PENNYBUSTER 02/15/18 05:18:13 PM
#9   CannTrust Holdings Inc. Receives Sales License from Health Canada jcamp212 02/12/18 02:53:47 PM
#8   What is not to like? JohnCM 01/28/18 12:58:35 PM
#7   Love it... PENNYBUSTER 01/28/18 12:14:17 PM
#6 JohnCM 01/27/18 11:58:53 PM
#5   I am in ... JohnCM 01/23/18 09:44:39 PM
#4   Added to ira account. PENNYBUSTER 01/23/18 11:29:33 AM
#3   CNBC Fast Money JohnCM 01/22/18 07:03:57 AM
#2   I was wrong. I was able to buy, JohnCM 01/10/18 11:04:13 PM
#1   This ticker is OTC GREY yet DTC eligible. JohnCM 01/10/18 09:15:25 AM